Vocalbeats.AI Achieves ISO/IEC 42001 Certification, Reinforcing Responsible AI Governance argenx and Zai Lab Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China
First–and–only approved FcRn antagonist for gMG patients by NMPA 68% of anti-AChR antibody positive gMG…
argenx and Zai Lab Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China
First–and–only approved FcRn antagonist for gMG patients by NMPA 68% of anti-AChR antibody positive gMG…
SciSparc Receives Approval to Conduct Phase IIb Clinical Trial for SCI-110 to Treat Tourette Syndrome in Germany
The Federal Institute for Drugs and Medical Devices in Germany granted the Company approval to…
SciSparc Receives Approval to Conduct Phase IIb Clinical Trial for SCI-110 to Treat Tourette Syndrome in Germany
The Federal Institute for Drugs and Medical Devices in Germany granted the Company approval to…
Capricor Therapeutics Announces Positive 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy
-Improvements in Left Ventricular Ejection Fraction (LVEF) for the Majority of Patients Suggest Preservation of…
Capricor Therapeutics Announces Positive 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy
-Improvements in Left Ventricular Ejection Fraction (LVEF) for the Majority of Patients Suggest Preservation of…
Data I/O Announces Gerald Ng as Vice President of Finance
REDMOND, Wash.–(BUSINESS WIRE)–Data I/O Corporation (NASDAQ:DAIO), the leading global provider of advanced security and data…
Semtech Adds Semiconductor Industry Leader to Board of Directors
Technology Executive Hong Q. Hou Joins Semtech to Help Oversee Next Era of Growth CAMARILLO,…
Capital Flows to Solar Power During the Energy Transition, an Industrial Info News Alert
SUGAR LAND, Texas–(BUSINESS WIRE)–Researched by Industrial Info Resources — The energy transition is apparent in…
California Resources Corporation Schedules Second Quarter 2023 Earnings Conference Call
LONG BEACH, Calif.–(BUSINESS WIRE)–California Resources Corporation (NYSE: CRC) plans to release its second-quarter 2023 financial…
IOG Resources Announces Senior Management Promotions and Promotes Tommy Woolley to Chief Executive Officer
DALLAS–(BUSINESS WIRE)–IOG Resources Management (“IRM”), the management company responsible for managing IOG Resources, LLC (“IOGR…
What to Look for in a Modern Insider Risk Solution
Insider threat can be described as the potential of an employee to utilize their authorised…
Reneo Pharmaceuticals to Participate in SVB Securities Therapeutics Forum
IRVINE, Calif., June 30, 2023 (GLOBE NEWSWIRE) — Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical…
Reneo Pharmaceuticals to Participate in SVB Securities Therapeutics Forum
IRVINE, Calif., June 30, 2023 (GLOBE NEWSWIRE) — Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical…
Ocugen CEO & CSO to Present at 41st Annual AAPI Convention and Scientific Assembly
MALVERN, Pa., June 30, 2023 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ:…
Ocugen CEO & CSO to Present at 41st Annual AAPI Convention and Scientific Assembly
MALVERN, Pa., June 30, 2023 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ:…
Novartis signs agreement to divest ‘front of eye’ ophthalmology assets in line with focused strategy
Divested assets to include Xiidra®, on-market treatment for dry eye disease and SAF312 (libvatrep), potential…
Novartis signs agreement to divest ‘front of eye’ ophthalmology assets in line with focused strategy
Divested assets to include Xiidra®, on-market treatment for dry eye disease and SAF312 (libvatrep), potential…
Madrigal Pharmaceuticals Announces Rolling Submission of New Drug Application to U.S. FDA Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis
Madrigal expects to complete full submission of the New Drug Application in July 2023 CONSHOHOCKEN,…
Madrigal Pharmaceuticals Announces Rolling Submission of New Drug Application to U.S. FDA Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis
Madrigal expects to complete full submission of the New Drug Application in July 2023 CONSHOHOCKEN,…